ScripsAmerica's International Distribution of RapiMed(R) to Include Over 300 Pharmacies and Hospitals in China

NEW CASTLE, Del., June 11, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC), a supplier of prescription and OTC drugs, today announced that Forbes Investments Ltd. (Forbes) has identified over 300 pharmacies and hospitals for the potential distribution of ScripsAmerica's RapiMed® product as part of joint-venture negotiations. The Company is currently in discussions with Forbes to market, supply, distribute and adapt its RapiMed® products throughout China's booming OTC market, valued at over $32 billion.

Jun Liang, Manager of Forbes Investments Ltd. in Shenzhen, China, said, "Forbes has already identified over 300 pharmacies and hospitals for the potential distribution of RapiMed®. This initial buying network has the ability to produce significant volume orders, setting the stage for further growth within the distribution network."

Liang continued, "RapiMed® is a truly unique and innovative product that has the ability to achieve significant market presence in China's booming OTC drug market. RapiMed® fast dissolving tablets do not require water and provide quick and effective delivery of medicine which is perfect for children, adults and the elderly. Additionally, China has been experiencing problems with counterfeit and dangerous medicine products, driving consumers to seek safe, reliable and effective OTC medications. ScripsAmerica's RapiMed® can satisfy that demand."

Bob Schneiderman, CEO of ScripsAmerica, concluded, "We are very excited about the potential to distribute RapiMed® in China and the growth opportunity that presents for ScripsAmerica and our shareholders. We have the ability to provide the extensive pharmacy and hospital networks Forbes is arranging with diverse and flexible RapiMed® product lines from pain relievers and fever reducers to vitamins to Erectile Dysfunction applications. This allows ScripsAmerica to meet the demand of multiple OTC medicine channels, resulting in potentially long-term, recurring revenue streams and record sales for the Company. We anticipate entering formal negotiations with Forbes in June and concluding with formal agreements by the end of September."

About ScripsAmerica, Inc.

ScripsAmerica, Inc. delivers pharmaceutical products to a wide range of end users across the health care industry through the largest pharmaceutical distributor in North America, McKesson Corporation. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies.

For more information, visit

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: 888-959-7095Source:ScripsAmerica, Inc.